Changing the Treatment Paradigm: Oral Therapeutics in Psoriasis & Melasma

Abstract

The management of chronic dermatologic conditions such as psoriasis and melasma has evolved significantly with the advent of novel oral therapeutics. This review critically examines the current landscape of oral medications for psoriasis and melasma, focusing on their mechanisms of action, efficacy, safety profiles, and place in contemporary treatment algorithms. By integrating the latest clinical trial data and guideline recommendations, this article aims to provide clinicians with a comprehensive understanding of the opportunities and challenges associated with oral therapies in these conditions, ultimately guiding evidence-based clinical decision-making.

Introduction

Psoriasis and melasma are prevalent dermatologic disorders with substantial physical and psychosocial impacts. While topical agents and phototherapy have traditionally been mainstays of treatment, limitations including incomplete response and patient inconvenience have driven exploration into systemic approaches. Oral therapeutics, both established and emerging, offer the potential for improved disease control and patient quality of life. This article reviews the epidemiology, pathophysiology, risk factors, clinical features, diagnostic criteria, therapeutic landscape, and evolving oral treatment options for psoriasis and melasma, with an emphasis on recent evidence and guideline-directed management.

Epidemiology / Disease Burden

Psoriasis affects approximately 2-3% of the global population, with higher prevalence in Northern Europe and lower rates in East Asia and sub-Saharan Africa. It is recognized as a systemic inflammatory disorder with comorbidities such as metabolic syndrome, cardiovascular disease, and depression. Melasma, by contrast, predominantly affects women of reproductive age, especially those with Fitzpatrick skin types III-V, and is more common in regions with high ultraviolet exposure. Both disorders are associated with significant cosmetic concerns, reduced self-esteem, and impaired quality of life, underscoring the need for effective and sustainable management strategies.

Pathophysiology

Psoriasis is characterized by dysregulation of the innate and adaptive immune system, with central involvement of Th17 and Th1 lymphocytes, overproduction of pro-inflammatory cytokines (e.g., IL-17, IL-23, TNF-α), and hyperproliferation of keratinocytes. Genetic susceptibility and environmental triggers contribute to disease manifestation. Melasma is a complex pigmentary disorder involving hyperactive melanocytes, increased melanin synthesis, vascular factors, and disruption of the dermal-epidermal junction. Hormonal influences (e.g., estrogen, progesterone), photodamage, and genetic predisposition play pivotal roles in its pathogenesis.

Risk Factors

Risk factors for psoriasis include a positive family history, obesity, smoking, chronic stress, infections (notably streptococcal), and certain medications such as lithium and beta-blockers. Melasma risk factors encompass genetic susceptibility, female sex, darker skin phenotypes, pregnancy, oral contraceptive use, hormone replacement therapy, and excessive sun exposure. Understanding these risk factors is critical for both prevention and tailored management.

Clinical Features

Psoriasis typically presents as well-demarcated, erythematous plaques with silvery scaling, commonly on the scalp, elbows, knees, and lower back. Variants include guttate, pustular, inverse, and erythrodermic forms. Nail involvement and psoriatic arthritis further complicate the clinical picture. Melasma is characterized by symmetric, hyperpigmented macules and patches, most commonly on the face (centrofacial, malar, or mandibular patterns). Lesions are often exacerbated by sun exposure and hormonal changes.

Diagnosis

Diagnosis of both conditions is primarily clinical, supported by characteristic morphology and distribution. In psoriasis, biopsy may be indicated in atypical cases. Severity assessment tools, such as the Psoriasis Area and Severity Index (PASI), facilitate therapeutic decisions. Melasma diagnosis relies on Wood\"s lamp examination and, in rare cases, histopathology to exclude other pigmentary disorders. Quality of life instruments and standardized scoring systems are increasingly utilized in both diseases to guide management and assess treatment response.

Treatment & Management

Traditional management of psoriasis incorporates topical corticosteroids, vitamin D analogs, coal tar, and phototherapy, escalating to systemic agents for moderate-to-severe disease. Conventional oral therapies include methotrexate, cyclosporine, and acitretin, each with distinct efficacy and safety considerations. Biologics have revolutionized care but are limited by cost and access. In melasma, first-line therapies consist of topical hydroquinone, triple combination creams, and photoprotection. Oral agents such as tranexamic acid, an antifibrinolytic, have gained prominence for recalcitrant cases. Additional oral interventions under investigation include antioxidants (polypodium leucotomos, glutathione), and tyrosinase inhibitors.

Recent Advances / Emerging Therapies

In psoriasis, the development of targeted oral small molecules such as apremilast (a phosphodiesterase-4 inhibitor) and the TYK2 inhibitor deucravacitinib offers new options for patients unsuitable for biologics. These agents provide efficacy with favorable safety profiles and greater convenience. For melasma, oral tranexamic acid has demonstrated efficacy in multiple randomized controlled trials, reducing hyperpigmentation via inhibition of plasminogen activation and subsequent melanocyte activity. Emerging evidence supports the role of oral antioxidants and anti-inflammatory agents as adjunctive therapies, though large-scale trials are ongoing.

Guideline Recommendations

International guidelines for psoriasis now incorporate apremilast and, most recently, deucravacitinib as oral options for moderate-to-severe disease, particularly in patients with contraindications to traditional immunosuppressants or biologics. Regular monitoring for adverse effects is emphasized. In melasma, guidelines from the American Academy of Dermatology and other bodies endorse oral tranexamic acid in refractory cases, with careful patient selection and monitoring for thromboembolic risk. Combination therapy remains the cornerstone for both conditions, optimizing efficacy while minimizing adverse effects.

Conclusion

The paradigm shift toward oral therapeutics in psoriasis and melasma reflects advances in understanding disease mechanisms and the need for patient-centered management. Recent oral agents expand the therapeutic armamentarium, offering effective, convenient, and often well-tolerated alternatives to traditional regimens. Ongoing research and real-world experience will further define their optimal use and long-term safety. Individualized treatment strategies, informed by clinical evidence and guideline recommendations, are essential to maximize outcomes in these chronic, burdensome conditions.